BioCentury | May 3, 2004
Company News

Remedyne board of directors update

Remedyne Corp. , Santa Barbara, Calif. Business: Cancer, Infectious Departed: Krisztina Zsebo, as president and CEO; she will join Enterprise Partners Venture Capital as a principal in the firm's life science group WIR Staff cancer Infectious...
BioCentury | May 3, 2004
Finance

Ebb & Flow

...science group, which is headed by Drew Senyei. Zsebo, who was president and CEO of Remedyne...
BioCentury | Dec 9, 2002
Company News

Remedyne, University of California deal

...antibodies, which Remedyne said is useful for treating tumor cells and those infected with viruses. Remedyne Corp....
BioCentury | Jul 15, 2002
Emerging Company Profile

Remedyne: Out, DAM spot

...DNA vaccine as a template to activate dendritic cell responses against cancer or viral diseases. Remedyne...
...with their respective wild-type antigens, and induces immunity in both tissues, according to the company. Remedyne...
...a vaccine against uropathogenic E. coli and NTH influenza for otitis media in preclinical development. Remedyne...
BioCentury | Jul 15, 2002
Emerging Company Profile

Corporate Profile

Remedyne Corp. Santa Barbara, Calif. Technology: Immune system modulation with bacterial carrier modified by DNA adenine methyltransferase of DNA vaccines Disease focus: Cancer, infectious diseases, animal health Clinical status: Preclinical Founded: 1999 by David Low,...
BioCentury | Mar 11, 2002
Company News

Remedyne, Bayer deal

...BAY granted Remedyne a license to its carcinoembryonic antigen (CEA) gene, for use in Remedyne's RemeStim-CEA...
...will have an option to acquire commercialization rights to RemeStim-CEA, which is in preclinical testing. Remedyne Corp....
BioCentury | Mar 4, 2002
Company News

Remedyne, Bayer CEA licensing deal

...Bayer (BAY; FSE:BAYG) granted Remedyne (Santa Barbara, Calif.) a non-exclusive license to its carcinoembryonic antigen (CEA...
...Santa Barbara, Calif.) a non-exclusive license to its carcinoembryonic antigen (CEA) gene, for use in Remedyne's...
BioCentury | Nov 12, 2001
Company News

Remedyne, Merial Ltd. deal

...The companies will develop animal therapeutics based on Remedyne’s DNA Adenine Methylase (DAM) technology. Under the...
...two-year agreement, Merial will fund feasibility studies on DAM-based vaccine product candidates and will pay Remedyne...
...license for all animal health applications identified. Remedyne will retain rights for human health applications. Remedyne Corp....
BioCentury | Nov 5, 2001
Clinical News

Remedyne preclinical data

...level of immune response than the natural immunity elicited in mice that survived virulent infection. Remedyne Corp....
BioCentury | Nov 5, 2001
Company News

Remedyne, Merial animal deal

...Vaccine company Remedyne (Santa Barbara, Calif.) partnered with animal health company Merial (London, U.K.) to develop...
...will fund Remedyne's R&D efforts to conduct feasibility studies on DAM-based vaccines, and will pay Remedyne...
...milestones. Merial will have the right to exclusively license products for animal health applications, while Remedyne...
Items per page:
1 - 10 of 13
BioCentury | May 3, 2004
Company News

Remedyne board of directors update

Remedyne Corp. , Santa Barbara, Calif. Business: Cancer, Infectious Departed: Krisztina Zsebo, as president and CEO; she will join Enterprise Partners Venture Capital as a principal in the firm's life science group WIR Staff cancer Infectious...
BioCentury | May 3, 2004
Finance

Ebb & Flow

...science group, which is headed by Drew Senyei. Zsebo, who was president and CEO of Remedyne...
BioCentury | Dec 9, 2002
Company News

Remedyne, University of California deal

...antibodies, which Remedyne said is useful for treating tumor cells and those infected with viruses. Remedyne Corp....
BioCentury | Jul 15, 2002
Emerging Company Profile

Remedyne: Out, DAM spot

...DNA vaccine as a template to activate dendritic cell responses against cancer or viral diseases. Remedyne...
...with their respective wild-type antigens, and induces immunity in both tissues, according to the company. Remedyne...
...a vaccine against uropathogenic E. coli and NTH influenza for otitis media in preclinical development. Remedyne...
BioCentury | Jul 15, 2002
Emerging Company Profile

Corporate Profile

Remedyne Corp. Santa Barbara, Calif. Technology: Immune system modulation with bacterial carrier modified by DNA adenine methyltransferase of DNA vaccines Disease focus: Cancer, infectious diseases, animal health Clinical status: Preclinical Founded: 1999 by David Low,...
BioCentury | Mar 11, 2002
Company News

Remedyne, Bayer deal

...BAY granted Remedyne a license to its carcinoembryonic antigen (CEA) gene, for use in Remedyne's RemeStim-CEA...
...will have an option to acquire commercialization rights to RemeStim-CEA, which is in preclinical testing. Remedyne Corp....
BioCentury | Mar 4, 2002
Company News

Remedyne, Bayer CEA licensing deal

...Bayer (BAY; FSE:BAYG) granted Remedyne (Santa Barbara, Calif.) a non-exclusive license to its carcinoembryonic antigen (CEA...
...Santa Barbara, Calif.) a non-exclusive license to its carcinoembryonic antigen (CEA) gene, for use in Remedyne's...
BioCentury | Nov 12, 2001
Company News

Remedyne, Merial Ltd. deal

...The companies will develop animal therapeutics based on Remedyne’s DNA Adenine Methylase (DAM) technology. Under the...
...two-year agreement, Merial will fund feasibility studies on DAM-based vaccine product candidates and will pay Remedyne...
...license for all animal health applications identified. Remedyne will retain rights for human health applications. Remedyne Corp....
BioCentury | Nov 5, 2001
Clinical News

Remedyne preclinical data

...level of immune response than the natural immunity elicited in mice that survived virulent infection. Remedyne Corp....
BioCentury | Nov 5, 2001
Company News

Remedyne, Merial animal deal

...Vaccine company Remedyne (Santa Barbara, Calif.) partnered with animal health company Merial (London, U.K.) to develop...
...will fund Remedyne's R&D efforts to conduct feasibility studies on DAM-based vaccines, and will pay Remedyne...
...milestones. Merial will have the right to exclusively license products for animal health applications, while Remedyne...
Items per page:
1 - 10 of 13